Screening for dysbetalipoproteinemia by plasma cholesterol and apolipoprotein B concentrations

Clinical Chemistry

Volumn 51, Issue 5, 2005, Pages 904-907

  Blom, Dirk J ^a   O'Neill, Frans H ^a   Marais, A David ^a,b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b Faculty of Health Sciences   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; CHOLESTEROL;

ADULT; AGAR GEL ELECTROPHORESIS; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; GENE MUTATION; GENETIC COUNSELING; GENOTYPE; HUMAN; HYPERLIPOPROTEINEMIA TYPE 3; IMMUNOTURBIDIMETRY; LIFESTYLE; LIPID COMPOSITION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PATIENT CODING; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRECIPITATION; RISK ASSESSMENT; SCREENING TEST; SENSITIVITY AND SPECIFICITY; TURBIDIMETRY; ULTRACENTRIFUGATION;

APOLIPOPROTEINS B; CHOLESTEROL; CHOLESTEROL, VLDL; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE III; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TRIGLYCERIDES;

EID: 17744379990     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2004.047001     Document Type: Article

References (24)

1. Mahley RW, Rall S. Type III hyperlipoproteinemia (dysbetalipoproteinaemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: Scriver A, Beaudet W, Sly S, Valle D, eds. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, 1995:1953-80.
2. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988;240:622-30.
3. Mahley RW, Huang Y, Rall SC Jr. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. J Lipid Res 1999;40:1933-49.
4. Blom DJ, Byrnes P, Jones S, Marais AD. Dysbetalipoproteinaemia-clinical and pathophysiological features. S Afr Med J 2002;92:892-7.
5. Civeira F, Pocovi M, Cenarro A, Casao E, Vilella E, Joven J, et al. Apo E variants in patients with type III hyperlipoproteinemia. Atherosclerosis 1996;127:273-82.
6. Stuyt PM, Van't Laar A. Clinical features of type III hyperlipoproteinaemia. Neth J Med 1983;26:104-11.
7. Morganroth J, Levy R, Fredrickson DS. The biochemical, clinical, and genetic features of type III hyperlipoproteinemia. Ann Intern Med 1975;82:158-74.
8. Masket BH, Levy RI, Fredrickson DS. The use of polyacrylamide gel electrophoresis in differentiating type 3 hyperlipoproteinemia. J Lab Clin Med 1973;81:794-802.
9. Blom DJ, Byrnes P, Jones S, Marais AD. Non-denaturing polyacrylamide gradient gel electrophoresis for the diagnosis of dysbetalipoproteinemia. J Lipid Res 2003;44:212-7.
10. Fredrickson DS, Morganroth J, Levy RI. Type III hyperlipoproteinemia: an analysis of two contemporary definitions. Ann Intern Med 1975;82:150-7.
11. Hazzard WR, Porte D Jr, Bierman EL. Abnormal lipid composition of very low density lipoproteins in diagnosis of broad-β disease (type 3 hyperlipoproteinemia). Metabolism 1972;21:1009-19.
12. Mishkel MA, Nazir DJ, Crowther S. A longitudinal assessment of lipid ratios in the diagnosis of type III hyperlipoproteinaemia. Clin Chim Acta 1975;58: 121-36.
13. Marcovina SM, Albers JJ, Kennedy H, Mei JV, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material. Clin Chem 1994;40:586-92.
14. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hhal. J Lipid Res 1990;31:545-8.
15. Warnick GR, Nauck M, Rifai N. Evolution of methods for measurement of HDL-cholesterol: from ultracentrifugation to homogeneous assays. Clin Chem 2001;47:1579-96.
16. Marz W, Feussner G, Siekmeier R, Donnerhak B, Schaaf L, Ruzicka V, et al. Apolipoprotein E to B ratio: a marker for type III hyperlipoproteinaemia. Eur J Clin Chem Clin Biochem 1993;31:743-7.
17. Nauck M, Glatt L, Marz W, Feussner G, Wieland H. Simple precipitation-based method for the screening of type III hyperlipoproteinemia. Clin Chem 1999;45:909-11.
18. Miller WG, Waymack PP, Anderson FP, Ethridge SF, Jayne EC. Performance of four homogeneous direct methods for LDL-cholesterol. Clin Chem 2002; 48:489-98.
19. Esteban-Salan M, Guimon-Bardesi A, de La Viuda-Unzueta JM, Azcarate-Ania MN, Pascual-Usandizaga P, Amoroto-Del-Rio E. Analytical and clinical evaluation of two homogeneous assays for LDL-cholesterol in hyperlipidemic patients. Clin Chem 2000;46:1121-31.
20. Okada M, Ishida R. Direct measurement of low-density-lipoprotein cholesterol is more effective than total cholesterol for the purpose of lipoprotein screening. Prev Med 2001;32:224-9.
21. Sniderman AD. Applying apoB to the diagnosis and therapy of the atherogenic dyslipoproteinemias: a clinical diagnostic algorithm. Curr Opin Lipidol 2004;15:433-8.
22. Genest J, Frohlich J, Fodor G, McPherson R. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ 2003;169:921-4.
23. Bachorik PS, Lovejoy KL, Carroll MD, Johnson CL. Apolipoprotein B and AI distributions in the United States, 1988-1991: results of the National Health and Nutrition Examination Survey III (NHANES III). Clin Chem 1997; 43:2364-78.
24. Sniderman AD, St. Pierre AC, Cantin B, Dagenais GR, Despres JP, Lamarche B. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol 2003;91: 1173-7.